NYSE · ARDT

Ardent Health, Inc.

$10.95 +$0.31 (+2.91%) 1D Pre-market

Key Metrics

$1.53B
Market cap
11.36×
P/E · TTM
$6.43B
Revenue · TTM
$134.28M
Net income
EPS · TTM $0.95
Dividend yield
Free cash flow
Beta · 1Y 1.20
EBITDA · TTM $449.24M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 4
    The stock moved +9.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 4
  • Jun 3
    The stock moved -15.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 3

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.53B
Enterprise value$2.03B
Shares outstanding143.4M
52-wk range$7.71 – $15.48
Avg volume · 20D430.1K
Net cash −$500.71M
Book value / share$9.50
IndustryServices-General Medical & Surgical Hospitals, Nec
ExchangeNYSE
About Ardent Health, Inc.
IPO dateJul 18, 2024
Employees25200

Ardent Health Inc is a provider of healthcare in growing mid-sized urban communities across the U.S and operating in eight growing mid-sized urban markets across six states Texas, Oklahoma, New Mexico, New Jersey, Idaho, and Kansas.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E11.36
P/S0.24
P/FCF
EV/EBITDA4.51
EV/Sales0.32
Graham №$14.28

Profitability

Gross
Operating 4.5%
Net 2.1%
FCF
ROE / ROIC 10.9% · 12.5%

Financial Health

Current ratio2.12
Quick ratio2.00
Debt / equity0.83
Debt / EBITDA 2.47
Net cash −$500.71M
Working capital$1.07B

Cash Flow · TTM

Operating CF $435.08M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

2.1
Grey zone (1.81–2.99) · monitor

Graham Number vs Price

$14.28 vs $10.95
Trades below classic defensive value — Graham-cheap
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings